Diet Exercise and ARmodafinil for obstructive sleep apnea (OSA) patients who cannot use standard treatments. (DEAR)

阻塞性睡眠呼吸暂停(OSA)影响着超过350万澳大利亚人，并与明显的白天嗜睡和注意力下降有关。这也是肥胖的常见健康并发症。许多人无法使用夜间佩戴的口腔夹板或口罩等标准治疗方法来治疗阻塞性睡眠呼吸暂停综合症。这项研究将着眼于用兴奋剂阿莫达非尼治疗日间嗜睡，同时通过饮食和生活方式的改变逐渐降低OSA的严重程度。

Obstructive sleep apnea (OSA) affects over 3.5 million Australians and is associated with marked daytime sleepiness and decreased concentration. It is also a common health complication of obesity. Many people are unable to use standard treatments for OSA in the form of a mouth splint or mask worn at night. This study will look at treating the daytime sleepiness with a stimulant medication, Armodafinil, whilst reducing OSA severity gradually with diet and lifestyle modification.